Atrium Therapeutics, Inc. RNA R2KR3KPHARMA
Company Overview
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company. The company was incorporated in 2025 and is headquartered in San Diego, California.
Why Investors Should Care
Revenue has grown at a 38.1% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $18.62M (+70.9% YoY); net profit $-76.68M.
- Trailing 12 Months Year-on-year growth — revenue +1148.3%.
- 5-Year Trend Long-term compounding — revenue CAGR 38.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 38.09% |
| 1 Year: | 1,148.30% |
Stock Price Performance
| 1 Year: | -3.80% |
| 6 Months: | -4.25% |
| 3 Months: | +20.25% |
| 1 Month: | +17.18% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- RSI (14)61.83 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 38.1% over 5 years.
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | RNA Atrium Therapeutics, Inc. R2KR3KPHARMA | 14.19 | -2.83 | $242.73M | 0.00% | -32.47% | -36.99% | 38.09% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue | 2.97M | 1.57M | 859.00K | 19.64M |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 47.22M | 9.03M | 48.89M | 36.91M |
| Operating Income | -44.25M | -7.45M | -48.03M | -17.28M |
| EBITDA | -44.19M | -7.40M | -47.91M | -17.13M |
| Interest Expense | - | - | - | - |
| Pretax Income | -44.24M | -7.45M | -48.03M | -16.63M |
| Tax Provision | 1.95M | - | 34.00K | - |
| Net Income | -46.20M | -7.45M | -48.07M | -16.63M |
| Diluted EPS | - | -0.44 | - | -0.97 |
| R&D Expense | - | 6.94M | - | 16.66M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Revenue | 9.76M | 10.90M | 18.62M |
| Cost of Revenue | - | - | - |
| Gross Profit | - | - | - |
| Operating Expenses | 16.15M | 24.11M | 95.43M |
| Operating Income | -6.39M | -13.22M | -76.81M |
| EBITDA | -6.25M | -13.05M | -76.49M |
| Interest Expense | - | - | - |
| Pretax Income | -6.38M | -13.22M | -76.83M |
| Tax Provision | 0 | 11.91M | -142.00K |
| Net Income | -6.38M | -25.12M | -76.68M |
| Diluted EPS | -0.37 | -1.47 | -2.89 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Total Assets | 10.29M | 7.19M | 278.35M |
| Current Assets | 856.00K | 483.00K | 272.85M |
| Cash & Equivalents | - | - | 270.00M |
| Inventory | - | - | - |
| Receivables | 751.00K | 0 | - |
| Total Liabilities | 80.91M | 68.29M | 71.07M |
| Current Liabilities | 33.80M | 26.80M | 41.80M |
| Long Term Debt | - | - | - |
| Total Debt | 9.85M | 6.80M | 3.67M |
| Total Equity | -70.62M | -61.11M | 207.29M |
| Shares Outstanding | 17.11M | 17.11M | 17.11M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | 56.39M | -22.55M | -41.13M |
| Investing Cash Flow | -320.00K | -266.00K | -1.45M |
| Financing Cash Flow | -56.07M | 22.82M | 42.57M |
| Capital Expenditure | -320.00K | -266.00K | -1.45M |
| Free Cash Flow | 56.07M | -22.82M | -42.57M |
| Net Change in Cash | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Gross Margin % | - | - | - |
| Operating Margin % | -65.4% | -121.3% | -412.6% |
| Net Margin % | -65.4% | -230.5% | -411.9% |
| ROE % | 9.0% | 41.1% | -37.0% |
| ROCE % | 27.2% | 67.4% | -32.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Sessa Capital IM, L.P. | 8.77% | 1.50M | $20.46M |
| 2 | Price (T.Rowe) Associates Inc | 8.61% | 1.47M | $20.09M |
| 3 | Blackrock Inc. | 8.46% | 1.45M | $19.74M |
| 4 | CRCM LP | 7.50% | 1.28M | $17.50M |
| 5 | Vanguard Capital Management LLC | 4.27% | 730.83K | $9.97M |
| 6 | TIG Advisors, LLC | 3.28% | 561.53K | $7.66M |
| 7 | Geode Capital Management, LLC | 2.26% | 386.93K | $5.28M |
| 8 | Two Sigma Investments, LP | 2.02% | 345.48K | $4.71M |
| 9 | Goldman Sachs Group Inc | 1.81% | 310.34K | $4.23M |
| 10 | 683 Capital Management LLC | 1.75% | 300.00K | $4.09M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for RNA
Wall Street Money Is Leaving Just As Atrium’s (RNA) Pipeline Turns Real
On August 13, Atrium Therapeutics (NASDAQ:RNA) reported second-quarter 2026 results that mixed real clinical progress with a familiar biotech question: how long the cash lasts. The company disclosed FDA clearance of its IND application for …
Atrium Therapeutics to Participate in Upcoming Investor Conferences
Atrium Therapeutics, Inc. (Nasdaq: RNA), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today announced that it will participate in upcoming investor conferences in September…
Atrium Therapeutics Reports Second Quarter 2026 Financial Results
Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics," or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today reported financial results f…
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on July 20, 2026 under the Company's 2026 Employment Inducement Incentive Award Plan (the "2026 Inducement Plan") as a material inducement …
Here's Why We're Not Too Worried About Atrium Therapeutics' (NASDAQ:RNA) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on April 20, 2026 under the Company's 2026 Employment Inducement Incentive Award Plan (the "2026 Inducement Plan") as a material inducement…
RNA — Frequently Asked Questions
What is the current share price of Atrium Therapeutics, Inc. (RNA)?
As of 2026-09-07 16:24 PDT, Atrium Therapeutics, Inc. (RNA) trades at $14.19 on NasdaqGS. Its 52-week range is $11.18 to $16.54.
What is the market capitalisation of RNA?
Atrium Therapeutics, Inc. (RNA) has a market capitalisation of $242.73M on NasdaqGS.
What is the P/E ratio of RNA?
RNA trades at a trailing price-to-earnings (P/E) ratio of -2.83. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 0.90.
What is the return on equity (ROE) of RNA?
RNA has a return on equity (ROE) of -36.99%. Its return on capital employed (ROCE) is -32.47%.
Is RNA a good stock to buy?
This page provides a data-driven analysis of Atrium Therapeutics, Inc. (RNA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.